Technologies gained one of their first solid footholds in the clinical care of cancer patients with adoption into the treatment paradigm of lung cancer, while researchers turned their eyes to proving utility in other niches.
There were fewer mergers and acquisitions in the omics space in 2017, breaking a two-year streak of growth — however, the deals themselves stayed fairly large.
Using Epstein-Barr virus DNA as a marker, investigators uncovered several individuals with early-stage nasopharyngeal cancers in a large screening effort in China.
Though researchers highlighted their goal of using the method to move toward a test to detect early cancers, their current data speaks only to the method's performance in late-stage cancer patients.
The approach, dubbed ThromboSeq, enables clinical researchers to identify different cancer types by looking at tumor-educated, platelet-derived RNA using RNA-seq.
In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.
